Understanding the survival impact of genetic changes in brain gliomas
Survival Significance and Clinical Characteristics of Molecular Pathology and Genetic Variation in Brain Gliomas
This study is trying to see how certain genetic changes in brain tumors called gliomas affect how long patients live and how well they respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 1 Year to 95 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Zhengzhou University Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT04216537 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather extensive clinical, radiological, pathological, molecular, and genetic data from patients with gliomas. It focuses on the classification of gliomas based on molecular and genetic biomarkers, including specific mutations and deletions. By analyzing this data, the study seeks to determine the prognostic and clinical significance of these biomarkers in relation to patient survival and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a confirmed diagnosis of primary glioma who are scheduled for tumor resection and have sufficient tissue for genetic analysis.
Not a fit: Patients without gliomas or those who cannot provide sufficient tumor tissue for molecular analysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and personalized treatment strategies for patients with gliomas.
How similar studies have performed: Other studies have shown promise in using molecular and genetic biomarkers to improve glioma classification and treatment outcomes, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Must have sufficient fresh frozen tissues for NGS * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfunctions * Do not have sufficient fresh frozen tissues for NGS
Where this trial is running
Zhengzhou, Henan
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Zhenyu Zhang, Dr.
- Email: fcczhangzy1@zzu.edu.cn
- Phone: +86 17839973727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.